XRPL 3.0.0 introduces TokenEscrowV1 to fix MPT escrow accounting with transfer fees, preventing LockedAmount supply drift. The amendment requires validator approvalXRPL 3.0.0 introduces TokenEscrowV1 to fix MPT escrow accounting with transfer fees, preventing LockedAmount supply drift. The amendment requires validator approval

XRPL Addresses Escrow Bug Impacting Institutional Tokenization Workflows

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • XRPL 3.0.0 introduces TokenEscrowV1 to fix MPT escrow accounting with transfer fees, preventing LockedAmount supply drift.
  • The amendment requires validator approval to activate, ensuring consistent escrow completion behavior across network nodes.

Ripple has released XRP Ledger version 3.0.0 and urged validators and node operators to upgrade without delay. The release targets an escrow accounting bug found during internal testing of token escrow for issued assets. Ripple said the fix supports consistent settlement behavior when institutions use time-locked or condition-based token delivery on XRPL.

Why This Crucial For The XRP Ledger

Escrow is a long-standing XRPL function used for scheduled transactions and conditional releases. It has historically worked with XRP only, which limited how issuers could use escrow for their own tokens. The XLS-85 Token Escrow proposal extends escrow to other issued assets, including IOUs and multi-purpose tokens, enabling escrowed delivery beyond XRP for enterprise workflows.

Multi-purpose tokens are an XRPL-native token format that blends fungible and non-fungible properties. They can carry shared traits while also storing asset-specific metadata on-chain. Developers describe them as suited for compliance tokenization because they can embed rules and lifecycle handling without relying on external smart contracts for core controls.

Internal testers of the original Token Escrow design, which has not been enabled on the main network, identified an accounting mismatch for Multi-Purpose Tokens that charge transfer fees. 

In a test case, an escrow locked one hundred tokens and applied a one-token transfer fee at unlock. The recipient correctly received ninety-nine tokens after the fee was applied. The issuer accounting, however, reduced the issuer’s LockedAmount by ninety-nine instead of the full one hundred. One token remained recorded as locked after completion, which would leave issuer metrics out of sync over time.

TokenEscrowV1 Separates Gross Escrow From Net Delivery

Version 3.0.0 includes the TokenEscrowV1 amendment, which changes how the ledger processes escrow completion for fee-bearing multi-purpose tokens. The amendment separates gross escrow accounting from net delivery accounting. 

When an escrow finishes, LockedAmount now decreases by the entire amount originally placed into escrow, returning to its pre-escrow level. Transfer fees are processed independently through the issuer’s fee mechanism, so only the net amount delivered affects outstanding supply calculations. The issuer’s transfer-fee mechanism accounts for the fee amount separately.

The network said this approach prevents tokens from remaining stuck in a locked state after escrow completion and keeps issuer LockedAmount metrics aligned with the ledger’s state. It linked the fix to institutional tokenization workflows that depend on accurate escrow accounting, including scheduled payouts, and automated treasury operations that use issued assets with transfer fees.

Because TokenEscrowV1 modifies core ledger processing, it requires activation through an amendment vote. Validators must approve the amendment to ensure nodes apply the same escrow completion rules across the network. Ripple asked operators to upgrade to version 3.0.0 so implementations remain compatible as the network moves toward activation.

The new XRP Ledger version 3.0.0 arrived weeks after Ripple expanded its Japan footprint through the Japan Financial Infrastructure Innovation Program, in a partnership with the Asia Web3 Alliance Japan and Web3 Salon.

At the time of writing, XRP traded at $2.33 after it rallied 9.34% over the past 24 hours.

]]>
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09